Contacts

Magali BALAVOINE

CONTACT

2 41 68 29 70 [email protected]

Katell LE DÛ, MD

CONTACT

[email protected]

Sponsors

Lead Sponsor

Weprom

Collaborators

Resilience
Incyte Corporation

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•1. Patient with untreated large B cell lymphoma requiring a first line treatment by RCHOP or R-mini-CHOP
•2. Patient aged 18 years or older at the time of signing Informed Consent Form
•3. Additional Intrathecal or/and intravenous treatment with Methotrexate allowed, if indicated
•4. Eastern Cooperative Oncology Group (ECOG) Performance Status \< 3
•5. Patient with internet access (or has someone at home who can help send patients' symptoms or complete the form)
•6. Patient enrolled in social security
•7. Patient has given his written consent ahead of any specific protocol procedure

Exclusion Criteria

•1. Patient with symptomatic brain metastases,
•2. Patient deprived of their liberty, under guardianship or trusteeship
•3. Patient is being treated for another cancer and has not been cured
•4. Patient with dementia, mental disorders or psychological pathology which could compromise patient informed consent and/or the observance of the study protocol
•5. Patient cannot submit to the protocol for psychological, social, familial or geographical reasons
•6. Patient is pregnant or breastfeeding

Related studies

RECRUITINGPhase 2

Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma

NCT07523737 · Primary Central Nervous System Lymphoma (PCNSL), Diffuse Large B Cell Lymphoma (DLBCL)

RECRUITINGPhase 1

KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT07260812 · Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL)

RECRUITINGPhase 1

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

NCT06451497 · Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, and more

RECRUITINGPhase 1/2

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

NCT05006716 · B-cell Malignancy, Marginal Zone Lymphoma, and more

RECRUITINGPhase 1

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

NCT06026319 · Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, and more

View all related studies →

Electronic MonitorIng of Events for dIffuse Large b Cell LYmphoma

What this study is about

Save this trial guide to your notes

Contacts

Sponsors

Related studies

Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma

KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

Trial snapshot

Condition

Locations shown

For caregivers